BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li N, Spetz MR, Li D, Ho M. Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3. Pharmacol Ther 2021;223:107892. [PMID: 33992682 DOI: 10.1016/j.pharmthera.2021.107892] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen G, Luo D, Zhong N, Li D, Zheng J, Liao H, Li Z, Lin X, Chen Q, Zhang C, Lu Y, Chan YT, Ren Q, Wang N, Feng Y. GPC2 Is a Potential Diagnostic, Immunological, and Prognostic Biomarker in Pan-Cancer. Front Immunol 2022;13:857308. [PMID: 35345673 DOI: 10.3389/fimmu.2022.857308] [Reference Citation Analysis]
2 Sun F, Yu X, Ju R, Wang Z, Wang Y. Antitumor responses in gastric cancer by targeting B7H3 via chimeric antigen receptor T cells. Cancer Cell Int 2022;22:50. [PMID: 35101032 DOI: 10.1186/s12935-022-02471-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
3 Musumeci F, Cianciusi A, D'Agostino I, Grossi G, Carbone A, Schenone S. Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma. Molecules 2021;26:7069. [PMID: 34885651 DOI: 10.3390/molecules26237069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]